Label-free techniques for Drug Discovery: Surface Plasmon Resonance (SPR) and MALDI Mass Spectrometry for Primary (HTS) and Secondary Screening
13 Aug 2018

The webinar will update on latest developments in MALDI mass spectrometry for high-throughput screening and CPD profiling (rapifleX MALDI PharmaPulse) and introduce Bruker's new surface plasmon resonance (SPR) instrument, the SIERRA SPR-32. Beside technical details explaining the latest developments, synergies between MALDI mass spectrometry and SPR will be discussed. In this webinar you will learn about: Primary and Secondary Screening in Drug Discovery Label-free technologies to reduce artefacts / importance of controls in SPR experiments Kinetic characterization: Determination of KDon- and KDoff-rates of compounds (SPR) Automation strategies to maximize throughput (SPR and MALDI)

Bruker Daltonics